This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 178 entries.
At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone. Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion. […]
While the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.” At […]
Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week. The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include: Progress with our BTX1801 antimicrobial program and plans for Phase 2 clinical studies in early 2022 Advancement of our BTX1702 clinical trial […]
According to WHO Director-General Tedros Adhanom Ghebreyesus, antimicrobial resistance is “one of the greatest health threats humanity faces today”. The Center for Disease Control and Prevention (CDC) estimates that each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. The reality is, #AMR can affect […]
With a successful track record of commercialising therapies in the antimicrobial space, and over 18 years of experience in senior commercial leadership within the pharmaceutical sector, Lynda Berne is well equipped to lead the commercial strategy for Botanix’s antimicrobial asset BTX1801. “BTX1801 is an extremely interesting therapy, as it is the first and only CBD […]
Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA. To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology […]
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update. Click here to view the report.
Botanix President and Executive Chairman, Vince Ippolito, was interviewed by Christine Corrado from Proactive’s New York studio yesterday. Their conversation focused on the recent launch of our BTX 1204A canine study for atopic dermatitis and our BTX 1702 rosacea study in Australia and New Zealand. In commenting on the potential for the atopic dermatitis study, […]
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs. Click here to view the report.
Botanix Pharmaceuticals (ASX:BOT) has today provided an update on its dermatology program, focusing on the BTX 1204A canine study for atopic dermatitis and BTX 1702 rosacea study. The BTX 1204A canine study for atopic dermatitis has now been launched. This will enrol 45 canines and evaluate two formulations of BTX 1204A. Positive data from a […]
